Congestive Heart Failure (CHF) is is a condition that affects every dimension of a patient’s life. While medicine has extended survival through advanced interventions like LVADs and transplants, the human cost of living with CHF remains immense.
Beyond the Numbers: What CHF Really Means
By definition, heart failure is the heart’s inability to pump enough blood to meet the body’s needs. It triggers a cascade of changes, causing sympathetic overdrive, and eventual cardiac remodeling. For patients, however, the medical jargon translates into :
• Shortness of breath (SOB): Climbing a single flight of stairs can feel like climbing a mountain.
• Fatigue: A constant weight that makes even simple tasks exhausting.
• Nausea and loss of appetite: Turning mealtime into yet another challenge.
The New York Heart Association (NYHA) staging reflects this progression—from mild limitations in Class I to complete inability to carry out activities in Class IV, where one-year mortality can reach nearly 40%.
The Rollercoaster of Decline
Unlike many illnesses that follow a steady decline, CHF often follows a rollercoaster pattern. Patients experience temporary recoveries after treatment, only to dip again with each hospitalization. These episodes of decompensation are both physically and emotionally draining—for patients and families alike.
Overlaying this journey are the constant threats of sudden cardiac death, strokes, and progressive decline, making planning for the future deeply uncertain.
The Complexities of Devices and Therapies
Advanced heart failure care has given us life-prolonging tools:
• Implantable Cardioverter Defibrillators (AICDs): Reduce the risk of sudden cardiac death but do not improve the quality of life. They also raise complex questions about deactivation at the end of life.
• Pacemakers: Lifesaving for some, but discontinuing pacing can hasten dying—a decision that carries emotional and ethical weight.
• LVADs: As destination therapy, they extend life, but at the cost of complications such as bleeding, stroke, and infection. Survival improves, but daily burdens often increase.
Patients and families must weigh years gained against the compromised quality of life .
The Overlooked Burden: Quality of Life
For many, the heaviest burden of CHF is not mortality. It is the loss of independence and dignity. Patients face:
• Repeated hospitalizations and ER visits.
• Dependence on caregivers for ADLs.
• Functional decline that strips away hobbies, work, and social connections.
• Cardiac cachexia (wasting syndrome), frequent breathlessness, and depression.
Despite advanced therapies, many live with profound physical and emotional suffering.
Why Palliative Care Matters
Palliative care doesn’t replace cardiology—it complements it. It addresses the gaps that medications and devices cannot:
• Symptom management for SOB and fatigue
• Emotional support for anxiety, depression, and uncertainty.
• Goals of care conversations to navigate difficult choices about interventions and future planning.
• Support for families and caregivers who often bear invisible burdens of their own.
The European Society of Cardiology highlights clear criteria for palliative integration which include progressive functional decline, dependence on daily care, frequent decompensations, poor quality of life, and ineligibility for transplant or advanced therapies.
Moving Forward
CHF represents a leading cause of death worldwide. Integrating palliative care early, alongside state-of-the-art cardiology, ensures patient-centered care.
References
Ward C. The need for palliative care in the management of heart failure. Heart. 2002; 87:294-298.
Braun TC, Hagen NA, Hatfield RE. Cardiac pacemakers and implantable defibrillators in terminal care. J Pain Symptom Manage. 1999; 18(2):126-131.
Allen LA, Stevenson LW, et al. Decision making in advanced heart failure: a scientific statement from the American Heart Association. Circulation. 2012; 125:1928-1952.
Cowger, J. A., Hall, S., Salerno, C. T., Naka, Y., Horstmanshof, D., Chuang, J., Wang, A., & Uriel, N. (2022). Five-Year Outcomes in Patients With Fully Magnetically Levitated vs Axial-Flow Left Ventricular Assist Devices in the MOMENTUM 3 Randomized Trial. JAMA, 328(12), 1233–1242. https://doi.org/10.1001/jama.2022.16197
Nunciaroni, A. T., Neves, I. F., Marques, C. S. G., Santos, N. D., Corrêa, V. F. A., & Silva, R. F. A. (2023). Palliative Care in Heart Failure: An Integrative Review of Nurse Practice. The American journal of hospice & palliative care, 40(1), 96–105. https://doi.org/10.1177/10499091221085276
Erin Campos, Sarina R. Isenberg, Leif Erik Lovblom, Susanna Mak, Leah Steinberg, Shirley H. Bush, Russell Goldman, Cassandra Graham, Dio Kavalieratos, Therese Stukel,Peter Tanuseputro, & Kieran L. Quinn. (2022). Supporting the Heterogeneous and Evolving Treatment Preferences of Patients With Heart Failure Through Collaborative Home-Based Palliative Care. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 11(19). https://doi.org/10.1161/JAHA.122.026319